Odyssey Therapeutics is focused on revolutionizing the treatment of autoimmune and inflammatory diseases by targeting upstream signaling mechanisms within the innate immune system. Their innovative approach aims to prevent pathological inflammation before it starts, contrasting with traditional therapies that typically address inflammation after it has occurred. By developing small molecule and protein therapeutics, Odyssey seeks to precisely target the underlying disease biology, particularly in conditions with significant unmet medical needs. Their pipeline includes promising candidates like the RIPK2 scaffolding inhibitor, which aims to block pro-inflammatory signaling pathways, and the IRAK4 scaffolding inhibitor, designed to disrupt inflammatory signaling at a critical junction in immune response.

The company emphasizes a deep understanding of immunobiology and employs advanced techniques in medicinal and computational chemistry to tackle complex therapeutic challenges. Their product candidates are designed to address issues such as cytokine redundancy, which is a limitation of existing treatments. By focusing on upstream immune responses, Odyssey's therapies have the potential to provide safer and more effective treatment options, whether used alone or in combination with other therapies. Their commitment to innovation is further supported by strategic collaborations with leading biotech and pharmaceutical companies, enhancing their ability to deliver transformative healthcare solutions to patients.

United States

At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine.

In response to recent recruitment fraud, visit our Careers page to verify all job opportunities and read our guidance on this topic: https://odysseytx.com/careers/

Odyssey Therapeutics

Company Details